Search Results - "Brieva, Luis"

Ozanimod Reduces Serum Neurofilament Light Chain (NfL) and Glial Fibrillary Acidic Protein (GFAP) and Modulates Innate and Adaptive Immunity in Patients with Low-to-Moderate Activity Relapsing–Remitting Multiple Sclerosis.

Authors: Costa-Frossard, Lucienne Brieva, Luis García-Estévez, Daniel Apolinar et al.

Source: International Journal of Molecular Sciences. Jun2026, Vol. 27 Issue 11, p4933. 17p.

Serum biomarkers at disease onset for personalized therapy in multiple sclerosis.

Authors: Monreal, Enric Fernández-Velasco, José Ignacio Álvarez-Lafuente, Roberto et al.

Source: Brain: A Journal of Neurology; Dec2024, Vol. 147 Issue 12, p4084-4093, 10p

Specific Proliferation Towards Myelin Antigens in Patients with Multiple Sclerosis During a Relapse.

Authors: Sáez-Torres, Irene Brieva, Luis Espejo, Carmen et al.

Source: Autoimmunity. Jan2002, Vol. 35 Issue 1, p45. 6p.

Lipidome analysis in multiple sclerosis reveals protein lipoxidative damage as a potential pathogenic mechanism.

Authors: Gonzalo, Hugo Brieva, Luis Tatzber, Franz et al.

Source: Journal of Neurochemistry. Nov2012, Vol. 123 Issue 4, p622-634. 13p. 3 Charts, 3 Graphs.

Profile of Cytokines Associated with SARS-CoV2 Seropositivity in Multiple Sclerosis Patients and Its Persistence over Six Months.

Authors: Sancho-Saldaña, Agustín Gil-Sánchez, Anna Quirant-Sánchez, Bibiana et al.

Source: Journal of Clinical Medicine. Jun2025, Vol. 14 Issue 11, p3736. 12p.

Novel Cell Models to Study Myelin and Microglia Interactions.

Authors: Santacreu-Vilaseca, Marta Moreno-Magallon, Judith Juanes-Casado, Alba et al.

Source: International Journal of Molecular Sciences. Mar2025, Vol. 26 Issue 5, p2179. 20p.

Relapse recovery in relapsing–remitting multiple sclerosis: An analysis of the CombiRx dataset.

Authors: Koch, Marcus W Moral, Ester Brieva, Luis et al.

Source: Multiple Sclerosis Journal. Dec2023, Vol. 29 Issue 14, p1776-1785. 10p.

Psychometric properties of the SDM-Q-9 questionnaire for shared decision-making in multiple sclerosis: item response theory modelling and confirmatory factor analysis.

Authors: Ballesteros, Javier Moral, Ester Brieva, Luis et al.

Source: Health & Quality of Life Outcomes. 4/22/2017, Vol. 15, p1-6. 6p.

Can Glatiramer Acetate Prevent Cognitive Impairment by Modulating Oxidative Stress in Patients with Multiple Sclerosis?

Authors: Gil-Sánchez, Anna Gonzalo, Hugo Canudes, Marc et al.

Source: Pharmaceuticals (14248247). Apr2024, Vol. 17 Issue 4, p459. 14p.

Hopelessness in Patients with Early-Stage Relapsing-Remitting Multiple Sclerosis.

Authors: de la Maza, Susana Sainz Maurino, Jorge Castillo-Triviño, Tamara et al.

Source: Patient Preference & Adherence. Jun2023, Vol. 17, p1431-1439. 9p.

Mitochondrial Aconitase Enzymatic Activity: A Potential Long-Term Survival Biomarker in the Blood of ALS Patients.

Authors: González-Mingot, Cristina Miana-Mena, Francisco Javier Iñarrea, Pedro José et al.

Source: Journal of Clinical Medicine. May2023, Vol. 12 Issue 10, p3560. 12p.

Measuring cognitive change in secondary progressive MS: an analysis of the ASCEND cognition substudy.

Authors: Leavitt, Victoria Mostert, Jop Comtois, Jacynthe et al.

Source: Journal of Neurology. May2025, Vol. 272 Issue 5, p1-12. 12p.

Seroprevalence of SARS-CoV-2 in a Cohort of Patients with Multiple Sclerosis under Disease-Modifying Therapies.

Authors: Sancho-Saldaña, Agustín Gil Sánchez, Anna Quirant-Sánchez, Bibiana et al.

Source: Journal of Clinical Medicine. May2022, Vol. 11 Issue 9, p2509-2509. 10p.

Psychometric Properties of the SymptoMScreen Questionnaire in a Mild Disability Population of Patients with Relapsing–Remitting Multiple Sclerosis: Quantifying the Patient's Perspective.

Authors: Meca-Lallana, José Maurino, Jorge Hernández-Pérez, Miguel Ángel et al.

Source: Neurology & Therapy. Jun2020, Vol. 9 Issue 1, p173-179. 7p.

Th1Th17CM Lymphocyte Subpopulation as a Predictive Biomarker of Disease Activity in Multiple Sclerosis Patients under Dimethyl Fumarate or Fingolimod Treatment.

Authors: Quirant-Sánchez, Bibiana Presas-Rodriguez, Silvia Mansilla, María José et al.

Source: Mediators of Inflammation. 6/26/2019, p1-9. 9p.

Predicting therapeutic response to fingolimod treatment in multiple sclerosis patients.

Authors: Quirant‐Sánchez, Bibiana Hervás‐García, José V. Teniente‐Serra, Aina et al.

Source: CNS Neuroscience & Therapeutics. Dec2018, Vol. 24 Issue 12, p1175-1184. 10p.

Improvements in quality of life over 2 years with cladribine tablets in people with relapsing multiple sclerosis: The CLARIFY-MS study.

Authors: Brochet, Bruno Solari, Alessandra Lechner-Scott, Jeannette et al.

Source: Multiple Sclerosis Journal. Dec2023, Vol. 29 Issue 14, p1808-1818. 11p.

A prospective study of cellular immune response to booster COVID-19 vaccination in multiple sclerosis patients treated with a broad spectrum of disease-modifying therapies.

Authors: Torres, Pascual Sancho-Saldaña, Agustín Gil Sánchez, Anna et al.

Source: Journal of Neurology. May2023, Vol. 270 Issue 5, p2380-2391. 12p.

Recommendations for the Diagnosis and Treatment of Multiple Sclerosis Relapses.

Authors: Ramo-Tello, Cristina Blanco, Yolanda Brieva, Luis et al.

Source: Journal of Personalized Medicine. Jan2022, Vol. 12 Issue 1, p6-N.PAG. 1p.

Abnormal sleep behavior caused by hypoglycemia.

Authors: Muñoz-Lopetegi, Amaia Pujol, Montserrat Giménez, Marga et al.

Source: Sleep Medicine. Sep2021, Vol. 85, p268-270. 3p.